| Literature DB >> 35010492 |
Massimiliano Carassiti1, Giuseppe Pascarella1, Alessandro Strumia1, Fabrizio Russo2, Giuseppe Francesco Papalia2, Rita Cataldo1, Francesca Gargano1, Fabio Costa1, Michelangelo Pierri3, Francesca De Tommasi4, Carlo Massaroni4, Emiliano Schena4, Felice Eugenio Agrò1.
Abstract
Low back pain represents a significant socioeconomic burden. Several nonsurgical medical treatments have been proposed for the treatment of this disabling condition. Epidural steroid injections (ESIs) are commonly used to treat lumbosacral radicular pain and to avoid surgery. Even though it is still not clear which type of conservative intervention is superior, several studies have proved that ESIs are able to increase patients' quality of life, relieve lumbosacral radicular pain and finally, reduce or delay more invasive interventions, such as spinal surgery. The aim of this narrative review is to analyze the mechanism of action of ESIs in patients affected by low back pain and investigate their current application in treating this widespread pathology.Entities:
Keywords: canal stenosis; disk herniation; epidural steroid injections; low back pain; lumbosacral radicular pain; review
Mesh:
Substances:
Year: 2021 PMID: 35010492 PMCID: PMC8744824 DOI: 10.3390/ijerph19010231
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Representative images of (A) intraoperative setting for CT and navigation guided epidural injection and (B) navigated needle insertion.
Figure 2Representative images of (A,B) navigated planning of needle path to the epidural space and (C,D) evidence of injection in the epidural space by the use of a contrast agent.
Epidural steroid injections for disk herniation studies.
| Author, Year | Study Design | Study Protocol | Outcome Measures | Summary of Findings | |
|---|---|---|---|---|---|
| Steroid Injection | Control | ||||
| Sariyildiz MA, 2017 [ | Prospective (repeated measures) | Transforaminal, 40 mg betamethasone + lidocaine 2% | Baseline | VAS, Oswestry Disability Index (ODI), hospital anxiety and depression scale, and Pittsburgh Sleep Quality Index (PSQI) | Compared to baseline measurements, there were significant improvements (> 50%) in radicular pain, ODI, depressive symptoms and PSQI scores at two weeks and 12 months after injection |
| Guclu B, 2020 [ | Prospective (repeated measures) | Transforaminal | Baseline | VAS scores at 12 weeks | Transforaminal epidural steroid injection is effective in relieving radicular pain, especially in paramedian lumbar disk herniation |
| Kennedy DJ, 2017 [ | Prospective | Transforaminal epidural steroid injection | Baseline | Presence of recurrent or persistent pain, pain within the previous week, current opioid use for radicular symptoms, need for additional spinal injections, progression to surgery and unemployment due to pain | Despite a high success rate at 6 months, the majority of subjects experienced a recurrence of symptoms at some time during the subsequent 5 years. Few reported current symptoms and a small minority required additional injections, surgery or opioid pain medications |
| Manchikanti L, 2014 [ | RCT, double-blind | Transforaminal 1% lidocaine, followed by 3 mg or 0.5 mL betamethasone | 1.5 mL 1% lidocaine + 0.5 mL sodium chloride | Numeric Rating Scale (NRS), Oswestry Disability Index 2.0 (ODI), opioid intake | At 2 years, there was significant improvement in all participants, although there was a lack of evidence of the superiority of steroids compared to local anesthetic |
| Manchikanti L, 2014 [ | RCT, double-blind | Interlaminar 0.5% lidocaine (6 mL) + 1 mL betamethasone | 0.5% lidocaine (6 mL) | Numeric Rating Scale (NRS), Oswestry Disability Index 2.0 (ODI), opioid intake | Improvement in 70% of the steroid group and 60% of the control group at the end of 2 years. |
| Manchikanti L, 2013 [ | RCT, double-blind | Interlaminar 0.5% lidocaine (5 mL) + 1 mL betamethasone | 0.5% lidocaine (6 mL) | Pain relief and functional status improvement of ≥ 50% | Average relief of 33.7 ± 18.1 weeks in the local anesthetic group and 39.1 ± 12.2 weeks in the local anesthetic and steroid group |
| Buchner M, 2000 [ | RCT | Interforaminal 100 mg methylprednisolone in 10 mL bupivacaine 0.25% | 10 mL bupivacaine 0.25% | VAS, straight leg raising test and functional status | No significance on pain relief, improvement of straight leg raising and improvement of functional status at 6 weeks and 6 months |
| Vad VB, 2002 [ | RCT | Transforaminal epidural steroid injection | Saline trigger-point injection | VAS, patient satisfaction scale, Roland–Morris low back pain questionnaire | At 1.4 years, the group receiving transforaminal epidural steroid injections had a success rate of 84%, vs. 48% for the control group |
| Butterman GR, 2004 [ | Prospective | Epidural steroid injection | Baseline | VAS, Oswestry Disability Index [ODI], pain diagram | At 2 years, it was beneficial for a small number of patients with advanced disk degeneration and chronic low back pain. It was more effective in discogenic inflammation |
| Manchikanti L, 2008 [ | RCT | Caudal epidural injections with 9 mL 0.5% lidocaine mixed with 1 mL steroid (6 mg betamethasone or 40 mg methylprednisolone) | Caudal epidural injections with 0.5% lidocaine 9 mL | NRS, ODI, opiod intake | Comparable efficacy in both groups at 12 months |
| Radcliff K, 2012 [ | Prospective | Epidural steroid injection | No epidural steroid injection | VAS, ODI, patient satisfaction | No improvement in short- or long-term outcomes (4 years) compared to patients who were not treated with ESIs |
| Şencan S, 2020 [ | Retrospective | Transforaminal epidural steroid injection | Baseline | NRS | A decreased pain scores at 1 h is a predictor for a favorable 3-month response to an ESI |
LDH = lumbar disk herniation; VAS = visual analogue scale; FU = follow-up; ESI = epidural steroid injections.
Epidural steroid injections for canal stenosis studies.
| Authors, Year | Study Design | Study Protocol | Outcome Measures | Summary of Findings | |
|---|---|---|---|---|---|
| Intervention | Control | ||||
| Sabbaghan S et al., | Retrospective, single arm | Bupivacaine hydrochloride 0.5% (3 mL) + triamcinolone acetonide 80 mg (2 mL) | Baseline | VAS for lumbar pain, VAS for lower limb pain and ODI | Improvement in pain (both lumbar than lower limb) and ability |
| Park CH et al., | Prospective, single arm | 2 mg preservative-free ropivacaine + 1500 units hyaluronidase + 40 mg triamcinolone acetonide | Baseline | 5-point patient satisfaction scale at 2 and 8 weeks post-treatment | The ESI seems to provide effective short-term pain relief from LSS. The grade of LSS appears to have no effect on the degree of pain relief |
| Cosgrove JL et al., | Prospective, single arm | Steroids, not specified | Baseline | Self-reported activity level and measured walking ability using the SSSQ and SMWT. The results were correlated through demographic data, magnetic resonance imaging (MRI) characteristics and electrodiagnostic results | Significant improvement as measured by changes in SMWT and SSSQ. Relative youth and female sex are associated with a more favorable response |
| Farooque M et al., | Case series | 10 mg dexamethasone (1 mL) + an equal volume of 2% preservative-free lidocaine on each side (transforaminal) | Baseline | Pain score and Swiss Spinal Stenosis score at baseline, 1, 3 and 6 months | Reduction of ≥ 50% in numeric pain scale score in 30% of participants at 1 month, 53% at 3 months and 44% at 6 months. Swiss Spinal Stenosis subscale scores indicated a significant reduction in the proportion of participants reporting the presence of severe pain in the back, buttocks and legs during FU compared to baseline ( |
| Hammerich A et al., | Randomized parallel-group trial | 1.5 mL steroid (not specified) at each site injected. Reassess at 3–4 and 6–8 weeks for potential second and third injections | 1.5 mL of steroid (not specified) at each site injected. Reassess at 3–4 and 6–8 weeks for potential second and third injections + physical therapy (PT) | Disability, pain, quality of life and global rating of change were collected at 10 weeks, 6 months and 1 year, and then analyzed using linear mixed model analysis | The ESI plus PT was not superior to ESI alone for reducing disability in individuals with LSS. |
| Brown LL et al., | Randomized controlled trial | 80 mg triamcinolone acetate (40 mg for diabetic patients) mixed with 6 mL preservative-free saline injected in divided doses at the treated levels | MILD procedure: a minimally invasive posterior lumbar decompression performed fluoroscopically through a small 6-gauge port | Visual Analog Scale, Oswestry Disability Index and Zurich Claudication Questionnaire (ZCQ) for patient satisfaction | MILD procedure was superior compared to ESI in pain reduction and the improvement of functional mobility |
| Kim HJ et al., | Prospective, single arm | 40 mg (1 mL) triamcinolone acetonide suspension + 1 mL bupivacaine hydrochloride 0.5% + 1 mL of saline | Baseline | Pain sensitivity questionnaire (PSQ), Oswestry Disability Index (ODI), and Visual Analog Scale (VAS) for back and leg pain | Significant decreases in VAS for back/leg pain and ODI 2 months after ESI. Individual pain sensitivity does not influence the outcomes of ESI treatment in patients with LSS |
| Campbell MJ et al., | Controlled clinical trial | Steroids (not specified) once a week for 3 weeks | Baseline | Spinal canal dimension, resolution of symptoms after ESI, necessity of surgery after ESI | Spinal canal dimension is not predictive of the success or failure of ESIs in patients with LSS |
| Milburn J et al., | Randomized controlled trial | 2 mL 40 mg/mL methylprednisolone + 2 mL bupivacaine 0.25% + 2 mL normal saline at the most stenotic level | 2 mL 40 mg/mL methylprednisolone + 2 mL bupivacaine 0.25% + 2 mL normal saline at 2 intervertebral levels cephalad of the level of maximal stenosis | Analog pain scale from 0 to 10 during ambulation and at rest, Roland–Morris Disability Questionnaire (RDQ) at baseline, immediately after ESI and at 1, 4, and 12 weeks post-injection | Symptom improvement is optimized when the ESI is performed at the intervertebral level of maximal stenosis |
| Bajpai S et al., | Randomized controlled trial | 5 mL bupivacaine (0.25%) + 2 mL methylprednisolone acetate (40 mg/mL) + 1 mL normal saline at maximal stenotic intervertebral level | 5 mL bupivacaine (0.25%) + 2 mL methylprednisolone acetate (40 mg/mL) + 1 mL normal saline 2 intervertebral levels cephalad to the level of maximal stenosis | Numeric Pain Rating Scale (NPRS) and Oswestry Disability Index (ODI) at 2, 6 and 12 weeks after the intervention | Pain relief improvement is optimized when the ESI is performed at the maximum stenotic intervertebral level |
| Koc Z et al., | Randomized controlled trial | Group 1: inpatient physical therapy program for 2 weeks | Group 3: no intervention | Pain severity by Visual Analog Scale (VAS), Finger Floor Distance (FFD) (cm), Treadmill Walk Test, Sit-to-Stand Test (Seconds), Weight-Carrying (WC) Test (Seconds) | Both ESI and physical therapy groups demonstrated an improvement in symptoms and in outcomes measured without any significant differences |
| Manchikanti L et al., | Randomized controlled trial | Local anesthetic (lidocaine 0.5%) 5 mL mixed + 6 mg betamethasone (1 mL) | 6 mL local anesthetic (lidocaine 0.5%) | Numeric Pain Rating Rcale (NPRS) and Oswestry Disability Index (ODI) at 3, 6, 12, 18 and 24 months post-treatment | Epidural injections of local anesthetic with or without steroids provide relief in a significant proportion of patients with LSS |
| Shamov T et al., | Prospective, two arms | Group 1: 10 mg dexamethasone in 3 cc 0.25% bupivacaine for patients with discogenic sciatica | Pain intensity was assessed by VAS at baseline and on days 1, 15 and 30 after intervention | ESIs are more effective in patients with discogenic sciatica than in single level LSS. In multiple level LSS, results are disappointing | |
| Friedly JL et al., | Randomized controlled trial | 1 to 3 mL 0.25% to 1% lidocaine followed by 1 to 3 mL triamcinolone (60 to 120 mg), betamethasone (6 to 12 mg), dexamethasone (8 to 10 mg) or methylprednisolone (60 to 120 mg) | 1 to 3 mL 0.25% to 1% lidocaine alone | Roland–Morris Disability Questionnaire (RDQ) and the rating of leg pain intensity (on a scale from 0 to 10) at 6 weeks after injection | Epidural injections of glucocorticoids plus lidocaine offered minimal or no short-term benefits compared to epidural injections of lidocaine alone |
| Makris UE et al., | Subsequent analysis of a randomized controlled trial (Friedly JL et al., | 1 to 3 mL 0.25% to 1% lidocaine followed by 1 to 3 mL triamcinolone (60 to 120 mg), betamethasone (6 to 12 mg), dexamethasone (8 to 10 mg) or methylprednisolone (60 to 120 mg) | 1 to 3 mL 0.25% to 1% lidocaine alone | RDQ (Roland–Morris Disability Questionnaire), Sickness Impact Profile (SIP) weights assigned to the RDQ items and patient-prioritized RDQ items at 6 weeks after injection | No significant difference between groups for the RDQ or patient-prioritized RDQ, and while the difference between groups for RDQ using SIP weights was statistically significant, this was not clinically important |
| Tomkins-Lane CC et al., | Prospective, single arm | Steroids, not specified | Baseline | Total activity (performance) measured over 7 days and maximum continuous activity (capacity), walking capacity was also assessed with the Self-Paced Walking Test and subjects completed the ODI, SSSQ, Medical Outcomes Study 36-Item Short-Form Health Survey, Visual Analog Pain scales and body diagrams | At 1 week postinjection, 58.8% of the subjects demonstrated increased total activity and 53% had increased maximum continuous activity, although neither change was statistically significant. |
| Rivest C et al., | Prospective, two arms | Group 1: 3 mL 0.5% lidocaine and 3 mL methylprednisolone acetate, followed by 3 mL saline for patients with LSS | Pain was assessed at baseline and 2 weeks following a single ESI using a Visual Analog Scale | LSS patients have worse responses to ESIs than herniated disk patients | |
| Fukusaki M et al., | Randomized controlled trial | Group 3: 8 mL 1% mepivacaine and 40 mg methylprednisolone | Group 1: 8 mL saline | Evaluation of improvement on pseudo-claudication associated with LSS as follows: excellent effect, > 100 m in walking distance; good effect, 20–100 m in walking distance; poor effect, < 20 m in walking distance | ESIs have no beneficial effects on walking ability associated with LSS compared to epidural injections with a LA alone |
ESI = epidural steroid injection; LSS = lumbar spinal stenosis; LA = local anesthetic; FU = follow-up; VAS = Visual Analog Scale; ODI = Oswestry Disability Index; SSSQ = Swiss Spinal Stenosis Questionnaire; SMWT = 6-Minute Walk Test; MRI = magnetic resonance imaging; PT = physical therapy; MILD = minimally invasive lumbar decompression; ZCQ = Zurich Claudication Questionnaire; PSQ = Pain Sensitivity Questionnaire; FFD = Finger Floor Distance; SIP = Sickness Impact Profile.